Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company.
It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases.
The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.
It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias.
The company was incorporated in 2007 and is headquartered in Seattle, Washington.
As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.28 Increased by 0.00% | -0.41 Increased by +31.71% |
| Mar 18, 24 | 0.12 Increased by +129.27% | -0.34 Increased by +135.29% |
| Nov 14, 23 | -0.24 Increased by +42.86% | -0.33 Increased by +27.27% |
| Aug 14, 23 | -0.27 Increased by +55.00% | -0.37 Increased by +27.03% |
| May 11, 23 | -0.28 Decreased by -12.00% | -0.37 Increased by +24.32% |
| Mar 23, 23 | -0.41 Increased by +21.15% | -0.27 Decreased by -51.85% |
| Nov 14, 22 | -0.42 Increased by +23.64% | -0.10 Decreased by -320.00% |
| Aug 11, 22 | -0.60 Decreased by -30.43% | -0.39 Decreased by -53.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 7.03 M Decreased by -25.09% | -17.92 M Decreased by -62.74% | Decreased by -254.81% Decreased by -117.25% |
| Dec 31, 23 | 30.85 M Increased by +1.01 K% | 5.96 M Increased by +131.59% | Increased by +19.32% Increased by +102.84% |
| Sep 30, 23 | 10.04 M Increased by +20.03% | -11.72 M Increased by +7.80% | Decreased by -116.72% Increased by +23.19% |
| Jun 30, 23 | 8.59 M Increased by +62.38% | -13.16 M Increased by +27.31% | Decreased by -153.10% Increased by +55.23% |
| Mar 31, 23 | 9.39 M Decreased by -31.12% | -11.01 M Decreased by -46.27% | Decreased by -117.29% Decreased by -112.37% |
| Dec 31, 22 | 2.78 M Decreased by -38.72% | -18.86 M Decreased by -24.38% | Decreased by -679.54% Decreased by -102.96% |
| Sep 30, 22 | 8.37 M Decreased by -1.75% | -12.71 M Increased by +5.78% | Decreased by -151.95% Increased by +4.10% |
| Jun 30, 22 | 5.29 M Decreased by -26.43% | -18.10 M Decreased by -64.09% | Decreased by -341.99% Decreased by -123.04% |